Neurofibromatosis
Also known as: Recklinghausen's disease, von Recklinghausen's disease
Methodology & AI Transparency ⓘ
Neurofibromatosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Neurofibromatosis is a genetic disorder of the nervous system.
- 2 Real-world patient consensus: Clinical coding for Neurofibromatosis uses ICD-10 Q85.00 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Differential triage of Neurofibromatosis (Q85.00) utilizes targeted/immunotherapy [Neurofibromatosis Q85.00].
- 4 Top reported side effects / signs: Objective lab/clinical target for Neurofibromatosis: Complete Blood Count in Neurofibromatosis (Q85.00: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (Q85.00)) and Comprehensive Metabolic & in Neurofibromatosis (Q85.00: Organ Function Panel).
Ask our AI Specialists anything about Neurofibromatosis
What Is Neurofibromatosis?
Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects how nerve cells form and grow. It causes tumors to grow on nerves. You can get neurofibromatosis from your parents, or it can happen because of a mutation (change) in your genes. Once you have it, you can pass it along to your children. Usually the tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1) causes skin changes and deformed bones. It usually starts in childhood. Sometimes the symptoms are present at birth. Type 2 (NF2) causes hearing loss, ringing in the ears, and poor balance. Symptoms often start in the teen years.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Neurofibromatosis (ICD-10 Q85.00) is driven by local tissue remodeling [Neurofibromatosis Q85.00]; Cross-referenced with NIH MeSH (Neurofibromatoses), specialists in Cancer, Oncology & Supportive Care monitor Comprehensive Metabolic & in Neurofibromatosis (Q85.00: Organ Function Panel) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Type 1 (NF1) causes skin changes and deformed bones. It usually starts in childhood. Sometimes the symptoms are present at birth
- • Type 2 (NF2) causes hearing loss, ringing in the ears, and poor balance. Symptoms often start in the teen years
- • Presentation of Neurofibromatosis (Q85.00): unexplained bleeding, chronic in Neurofibromatosis (Q85.00: hoarseness/cough, or progressive)
- • Secondary Neurofibromatosis clinical sign: abnormality detected early in Neurofibromatosis (Q85.00: on age-appropriate screening)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Neurofibromatosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q85.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Neurofibromatosis (Q85.00: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (Q85.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Neurofibromatosis (Q85.00: Organ Function Panel) | Preserved renal/hepatic clearance (Q85.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Neurofibromatosis (Q85.00: Genomic Staging) | Guideline-concordant surveillance (Q85.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Neurofibromatosis
Treatment selection for Neurofibromatosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neurofibromatosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Within-trial hospitalization resource utilization and budget impact analysis for The addition of darolutamide to docetaxel + ADT was associated with a numerically lower rate of hospitalization but marginally longer LoHS compared with docetaxel + ADT alone. Journal of managed care & specialty pharmacy • 2024-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38807035 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient- and clinician-assessed five-year normal tissue effects following Five-year patient-reported normal tissue effects suggest 26 Gy/5Fr/1-week hypofractionation is safe for breast cancer patients requiring adjuvant axillary radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-06-15 • Phase III Randomized Trial | N = 172 | 82/100 | PMID 40379410 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Of 158 patients included, the median (IQR) age was 54 (43-61) years, and 140 (88.6%) patients were male. JAMA surgery • 2024-06-01 • Phase III Randomized Trial | N = 158 | 82/100 | PMID 38568599 ↗ |
| Can This Approach Help? Inside the Latest Research on Estradiol/Micronized Progesterone vs. Conjugated Equine Sixteen genes involved in mammary tumor inclination were subject to Q-PCR, inclining the CEE/MPA group towards an increased risk for breast carcinoma compared to the E 2 /P group at a very high significance level ( p = 3.1 ×... International journal of molecular sciences • 2023-02-18 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 36835533 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens Conclusion:. Journal of comparative effectiveness research • 2024-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39162049 ↗ |
Neurofibromatosis Patient Community & “People Like Me” Threads
Filter Neurofibromatosis community threads and patient logs by age, biological sex, dosage, and treatment duration.